当前位置： SCI文献检索 > Oxidative Medicine and Cellular Longevity期刊下所有文献 > Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.

Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.

Abstract：

:The incidence of prostate cancer (PCa) is increasing, and it is currently the second most frequent cause of death by cancer in men. Despite advancements in cancer therapies, new therapeutic approaches are still needed for treatment-refractory advanced metastatic PCa. Cross-species analysis presents a robust strategy for the discovery of new potential therapeutic targets. This strategy involves the integration of genomic data from genetically engineered mouse models (GEMMs) and human PCa datasets. Considering the role of antioxidant pathways in tumor initiation and progression, we searched oxidative stress-related genes for a potential therapeutic target for PCa. First, we analyzed RNA-sequencing data from Pb-Cre4; Ptenf/f mice and discovered an increase in sulfiredoxin (Srxn1) mRNA expression in high-grade prostatic intraepithelial neoplasia (PIN), well-differentiated adenocarcinoma (medium-stage tumors), and poor-differentiated adenocarcinoma (advanced-stage prostate tumors). The increase of SRXN1 protein expression was confirmed by immunohistochemistry in mouse prostate tumor paraffin samples. Analyses of human databases and prostate tissue microarrays demonstrated that SRXN1 is overexpressed in a subset of high-grade prostate tumors and correlates with aggressive PCa with worse prognosis and decreased survival. Analyses in vitro showed that SRXN1 expression is also higher in most PCa cell lines compared to normal cell lines. Furthermore, siRNA-mediated downregulation of SRXN1 led to decreased viability of PCa cells LNCaP. In conclusion, we identified the antioxidant enzyme SRXN1 as a potential therapeutic target for PCa. Our results suggest that the use of specific SRXN1 inhibitors may be an effective strategy for the adjuvant treatment of castration-resistant PCa with SRXN1 overexpression.

journal_name

Oxid Med Cell Longev

journal_title

Oxidative medicine and cellular longevity

authors

Barquilha CN,Santos NJ,Monção CCD,Barbosa IC,Lima FO,Justulin LA,Pértega-Gomes N,Felisbino SL

doi

10.1155/2020/2148562

subject

Has Abstract

pub_date

2020-01-20 00:00:00

pages

2148562

eissn

1942-0900

issn

1942-0994

journal_volume

2020

pub_type

杂志文章

在线工具

Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.